Rapid Preclinical Screening of Chemotherapeutic Agents Effective in Combination With Immunotherapy  by Lucas, P.J. et al.
Poster Session II S337512
RAPID PRECLINICAL SCREENING OF CHEMOTHERAPEUTIC AGENTS
EFFECTIVE IN COMBINATION WITH IMMUNOTHERAPY
Lucas, P.J., Sivarapatna, A., Wang, J., Gress, R.E. National Institutes of
Health, Bethesda, MD
Therapeutic alternatives are extremely limited for patients with
disease relapse following allogeneic marrow transplantation. One ap-
proach has been to intensify the immunotherapy of transplantation
by infusion of lymphocytes upon disease relapse (delayed lymphocyte
infusion, DLI). Administration of DLI can be limited by graft versus
hostdisease, and its effectivenessby tumor accessibility, suppressive lo-
cal tumor environment, low tumor antigenicity, and systemic immune
tolerance. Recent studies have shown that certain chemotherapeutic
agents, especially those with knownmolecular targets, can be effective
in combinationwithDLI to eliminate residual tumor.Toassess the ef-
fectiveness of targeted chemotherapeutic agents in conjunction with
DLI, we have developed a series of in vitro and in vivo murine assays
to screen potential agents for combinationDLI therapy. In vitro tissue
culture with flow cytometric analysis using annexin, propidium iodine,
and CFSEmarkers is used to establish tumor susceptibility and effec-
tive dose for each chemotherapeutic agent.Characterizationof adverse
in vivo effects on relevant immune effector and regulatory populations,
such asmemory and na€ıveT, antigen presenting, NK andTreg cells is
then assessed using drug titration in a thymectomizedmousemodel to
avoid the variable of thymic derivedT cell renewal. Finally, optimized
drug concentrations are used in an allogeneic graft versus tumor
(GVT) model to screen for additive or synergistic effects on tumor
growth in conjunction with DLI. Using these screening methods we
have been able to rapidly identify useful chemotherapeutic agents,
and establish drug concentrations capable of improving survival over
GVT effects associated with DLI alone. In addition, in vitro drug
effectiveness, as measured by cell membrane injury, cell death and
decreased cell proliferation, has been an effective tool to predict
in vivo anti-tumor responses.513
TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE WITH BASILIXIMAB AND ETANERCEPT IN EARLY PERIOD
Tan, Y., Luo, Y., Shi, J., He, J., Zhao, Y., Lai, X., Zheng, W., Sun, J.,
Zheng, Y., Cai, Z., Lin,M., Huang, H. The First Affiliated Hospital, Zhe-
jiang University School of Medicine, Hangzhou, Zhejiang Province, China
Background: Severe acute graft-versus-host disease (aGVHD) is
a life-threatening complication after allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Steroid-resistant aGVHD(SR-
aGVHD) is especially associated with a high incidence of mortality.
Methods:We performed a prospective study in treatment of grades
III-IV SR-aGVHD in early period with a combination of anti-cyto-
kine therapy composed of IL-2 receptor antibody (basiliximab) and
TNF-receptor fusion protein (etanercept) from June 2009 to Agust
2010. Seven patients experienced grade IV SR-aGVHD (skin in-
volved in seven patients, gastro-intestinal involved in six patients,
liver involved in four patients). The median age was 23 years (range
11-48). Donor types were HLA-matched related (n 5 1), HLA-
matched unrelated (n 5 2), and haploidentical related (n 5 4).
Anti-cytokine therapy consisted of intravenous basiliximab 20mg
on days 1, 4, 8, 15, and etanercept 25 mg subcutaneous twice
a week for 4 weeks, followed by once weekly for 4 more weeks.
Results: All patients (100%) achieved complete remission. Five of 7
(71.4%) patients are currently alive with a median follow-up of 163
(80–348) days after transplantation, and a median follow-up of 121
(48–321) days after Anti-cytokine therapy. Only two patients died
of pulmonary infection and cardiac arrest. In our retrospectivly
studied in twenty-three patients with SR-aGVHD who reveiving
allo-HSCT from HLA-matched related donor (n 5 1), HLA-mis-
matched related donor (n 5 1),HLA-matched unrelated donor
(n 5 6), HLA-misatched unrelated donor (n 5 15), the treatment
of SR-aGVHD included high dose methylprednisolone, anti-thy-
mocyte globulin, basiliximab or etanercept, respectively. Only five
(21.7%) patients achieved CR and two(8.69%) achieved partial
remission. Only five of 23 (21.7%) patients are currently alive with
a median follow-up of 52 (32–3697) days after transplantation.The
incidence of treatment-related mortality (TRM) was 78.3%. The
cause were infectious complications and organ failure.Conclusion: Inflammatory cytokines, IL-2 and TNF-a, play critical
roles in the pathological of GVHD, and may be effective targets for
therapy. Our data suggested that the combination of basiliximab and
etanercept is well tolerated and can induce a high response rate, high
survival rate with low incidence of TRM in patients with severe SR-
aGVHD in early period, particularly in sever GrmonaryI aGVHD.514
MYELOABLATIVE UNRELATED CORD BLOOD TRANSPLANTATION FROM
GRAFTS WITH THREE HLA ANTIGEN MISMATCHES RESULTED IN SUPE-
RIOR OUTCOMES FOR PATIENTS WITH DE NOVO ACUTE LEUKEMIAS
Tsukada, N.1, Takahashi, S.1, Ooi, J.1, Kato, S.1, Kawakita, T.1,
Nagamura, F.1, Yamaguchi, T.2, Tojo, A.1, Asano, S.1 1 Institute of
Medical Science, University of Tokyo, Tokyo, Japan; 2University of Tokyo,
Tokyo, Japan
Westudied the clinicaloutcomesof 87 adultswithdenovoacute leu-
kemias who received unrelated cord blood transplantation (CBT) after
myeloablative conditioning. Between August 1998 and July 2008, 55
patients with acute myelogenous leukemia (AML) and 32 patients
with acute lymphoblastic leukemia (ALL) were treated with unrelated
CBT. All patients received 4 fractionated 12 Gy total body irradiation
(TBI) and chemotherapy asmyeloablative conditioningandcyclospor-
ine plus short termmethotrexate as graft-versus-host disease (GVHD)
prophylaxis. The median age was 38 years and the median number of
nucleated cells was 2.38 x 107/kg. 16 patients were transplanted not
in complete remission (CR). t(9;22) and 11q23 abnormalities were
found in nine and seven, respectively. All patients received a single
cord blood unit and grafts were selected from at least 4/6 serologically
matched units in the Japan Cord Blood BankNetwork. Variables con-
sidered in statistical analyses were age, gender, diagnosis, disease status
at CBT, disease risk, cytogenetic subgroups, total nucleated cell
(TNC) dose, sex mismatches, ABO mismatches, HLA mismatches
(A andBby low resolution,DRB1by high resolution), and blood levels
of cyclosporine. With a median follow-up of 42 months (range
13-120), the probability of disease free survival (DFS) at 5 years was
67.1% (95%CI: 57.0-77.2%). The 5-year cumulative incidence of re-
lapse was 23.1% (95%CI: 13.7-32.5%). In multivariate analysis, the
risk factor identified for both DFS and the incidence of relapse was
the numbers of HLA mismatches. The probability of DFS and the
cumulative incidence of relapse in the subset of three HLA antigen
mismatches (n 5 25) were 89.6% and 9.9%, respectively. Several re-
ports have shown thatHLAmatchedCBT resulted in better outcome,
but our study revealed superior outcome in recipients of grafts with
three HLA antigen mismatches. Although this is a result from a Japa-
nese single institute, we suggest that CBT from grafts with threeHLA
antigenmismatchesmay improve outcomes by reducing the incidence
of relapse without increasing treatment related mortality (TRM) in
adult patients with de novo acute leukemias.515
SINGLE DOSE ADMINISTRATION OF ECP TREATED CELLS PRIOR TO
TRANSPLANTATION SIGNIFICANTLY INCREASES SURVIVAL IN A MHC-
MISMATCHED MODEL OF ACUTE GVHD
Florek, M., Sega, E.I., Leveson-Gower, D.B., Gill, S., Mueller, A.M.S.,
Negrin, R.S. Stanford University, Stanford, CA
Extracorporeal photophoresis (ECP) has shown promise as a ther-
apeutic modality in treating steroid-resistant chronic and acute
GvHD. The way ECP mediates its effect has not been clearly eluci-
dated, but some of the proposed mechanisms include impaired mat-
uration of dendritic cells and reduced antigen presentation induced
by apoptotic cells, as well as increased regulatory T (Treg) cells.
We have developed a pre-emptive murine model of ECP to inhibit
the initiation phase of acute GvHD and improve survival.
Methods: Apoptosis was induced by ECP using 8-Methoxypsoralen
and UVA light (UVAR light set, Therakos). Two days prior to bone
marrow transplantation (BMT), 10^7 syngeneic (BalbC;H2-d) or allo-
geneic (C57BL6;H2-b) splenocytes treatedwithECPwere infused into
BalbC recipients. To induce acute GvHD mice received 0.75x10^6
conventional T cells (Tcon) and 5x10^6 T cell depleted bone marrow
from C57BL6 (H2-b). Animals were followed for survival, and GvHD
was scoredusing standard criteria. In someexperiments,Tconwerede-
rived from luciferase-transgenic animals, allowing for quantification of
T cell proliferation using bioluminescent imaging (BLI).
